Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04585516
Other study ID # 274964
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date January 2028

Study information

Verified date October 2020
Source Region Örebro County
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The number of endoscopies performed varies greatly between different countries and does not reflect variations in disease incidents. The costs of unnecessary endoscopies are significant and with a better selection of which patients need to be examined with endoscopy, resources could be saved in healthcare, and a better triage would mean that malignancies and other more serious conditions do not have to wait. An example of unnecessary endoscopy is a colonoscopy in patients with irritable bowel syndrome or gastroscopy in patients with functional dyspepsia.

The purpose of the project is, among other things:

- What diagnostic benefit have gastroscopy, colonoscopy, capsule endoscopy and double balloon enteroscopy for different indications in different age groups?

- What are the risks of this type of examination?

- Can patients be better selected based on symptoms, psychometric data or laboratory findings to reduce the number of unnecessary examinations and prioritize those that should be scooped up first?

- Can changed calling methods reduce the number of late cancellations and rebookings and missed patients?


Description:

1: Identification of colorectal cancer in Örebro Region - Effectiveness of Standardised Course of Care.

Introduction: To shorten time to diagnosis of suspected colorectal cancer (CRC) in Sweden, CRC was included in the "standardised course of care" (SCC) in 2016. However, not all patients with CRC are referred via the SCC, and CRC is also found in patients undergoing a routine colonoscopy.

Objective: To identify CRC cases in the Örebro Region and how they were identified. Furthermore, to investigate the reasons for and possible effect of not being included in the SCC-CRC for cases found via colonoscopy.

Methods: Reviewing medical records of patients with CRC referred to the Clinic of Surgery in the Örebro Region in 2016-2018 (n=459).

The information recalled from the journals includes diagnostic pathway of CRC discovery, age, gender, Body Mass Index (BMI), Hb-value, date of referral to colonoscopy, date of preformed colonoscopy, referral route (SCC-CRC or non-CRC-SCC), reasons for referral (including SCC-CRC criteria) and patient symptoms. Furthermore, we will gather data of tumor localization (caecum; ascending colon; splenic flexure; transverse colon; hepatic flexure; descending colon; sigmoid and rectum), TNM-stage of the tumor, [11] tumor differentiation (high grade or low grade tumor), and source of referral (referral by general practitioner or referral by hospital physician).

Age is determined at the time of referral. BMI is defined as the most recent BMI value at time of referral within six months prior or six months after referral date. Hb-value will be defined as the most recent Hb-value within a month prior of the time of referral. Diagnostic interval is defined as the number of days days between the referral and the colonoscopy. When the tumor localization is described as in between two locations of the colon (e.g. descendent colon and sigmoid colon) the most proximal location is chosen for statistical analysis. Patients with two or more synchronous cancers are registered as more than one incident per case. When the tumor localization is described as being present in the rectosigmoid transition, the sigmoid is used as the tumor localization in the analysis. When patients have two or more symptoms and reasons for referral, data are registered as more than one incident per case. TNM stage is converted to tumor stage I-IV. [1] When patients have one or more synchronic cancer with different TNM stages, the highest cancer stage is chosen for analysis. If the TNM stage is not fully known (e.g. information about lymph nodes and metastases are missing) the stage is set as no lymph node engagement or metastases, If the original referral cannot be found, date and reasons for referral are collected from journal entries.

2: The Swedish standardized course of care for colorectal cancer - cancer prevalence and predictive values of entry criteria.

Introduction: To shorten waiting times for cancer treatment and to reduce national inequalities in cancer care, the standardized course of care (SCC) was implemented in Sweden. The SCC for colorectal cancer (CRC-SCC) was implemented in 2016. Since then, about 46.000 patients have been examined according to a CRC-SCC. However, few studies have been conducted to evaluate the CRC-SCC.

Aim: To identify the prevalence of colorectal cancer (CRC) in patients referred to Örebro University Hospital (USÖ) according to a CRC-SCC. We also aimed to investigate the positive predicting values (PPVs) and odds ratios (ORs) of different SCC-criteria with respect to CRC.

Method: Medical record review including all patients examined by colonoscopy as part of a CRC-SCC-referral to USÖ between September, 2016 and December 2018 (n=1271).The parameters of interest include; patient characteristics such as sex and age, the SCC-criteria for reasonable suspicion of cancer. If the patient has an altered bowel function it is registered whether the patient has loose stool, constipation, a combination of the two, or not specified in the referral. Rectal bleeding is defined as fresh rectal bleeding, excluding melaena. Patients who fulfill multiple criteria are registered as more than one incidence case. Laboratory values such as fecal occult blood, plasma-hemoglobin, and fecal-calprotectin (F-calprotectin) are registered. The most resent value at the time of referral is used. If there is no value within a month of the referral, no value was registered. A patient is regarded to have a positive fecal occult blood test (FOBT) if at least one out of three tests is positive. A f-calprotectin <50mg/kg is considered negative. Findings from the colonoscopy such as CRC, polyps, inflammation of the colon, diverticulosis, hemorrhoids, angiodysplasia or no finding are registered. All findings with colonoscopy are, if possible, histologically verified.

3: Why do we perform gastroscopy in younger patients?

Background: Esophagogastroduodenoscopy (EGD) is the golden standard diagnostic method in upper GI pathologies. The current guidelines indicate that patients with alarm symptoms and/or dyspeptic patients over 50 years of age should be readily investigated with gastroscopy. However, EGD is also frequently performed in the younger population, where it often results in absence of pathological findings. In Örebro approximately 4000 EGD are completed yearly, approximately 40% of the EGD's are performed in patients >50 years, requiring extensive resources.

Aim: to identify factors in the EGD referrals of patients under 50 years of age without alarm symptoms, in order to minimize the number of unnecessary EGD's in this age group.

Method and material: The study will be conducted as a retrospective database study. We will process the EGD referrals and diagnostic findings of young patients (age 18-50 y) performed during 2017-2019 at Örebro University Hospital. Statistical analysis will be performed to identify which signs and symptoms are associated with a pathological finding during EGD and which signs and symptoms are associated with a negative finding. The parameters of interest include; patient characteristics such as sex and age will separately analyze the groups 18-29y, 30-39y, and 40-49 y. Other parameters include: BMI, ethnicity, use of NSAID/ASA, h. pylori analysis, eventual treatment for h. pylori, smoking, alcohol consumption,presence of GI disease before gastroscopy, previously done gastroscopy, source of referral (primary health care or in-hospital patients), if present: fulfillment of Rome IV criteria for functional dyspepsia, symptoms such as anemia, fecal occult blood, palpable mass in abdomen, weight loss, loss of appetite, dysphagia, vomiting, jaundice, waiting time between referral and gastroscopy, as well as the findings under gastroscopy; GERD/oesofagitis, peptic ulcus, gastritis, dysplasia/cancer, IBD, celiac disease, hiatal hernia


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 5000
Est. completion date January 2028
Est. primary completion date January 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

All patients who underwent a diagnostic diagnostic procedure at the endoscopy unit at the University Hospital Örebro.

Exclusion Criteria:

Patients <18 years

Study Design


Intervention

Procedure:
endoscopy
Colonoscopy or gastroscopy

Locations

Country Name City State
Sweden University hospital Örebro Egion Rebro Ounty

Sponsors (1)

Lead Sponsor Collaborator
Region Örebro County

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient characteristics in patients who were admitted for colonoscopy 1 proportion of patients with weight loss >10% September 2016 - December 2018
Other Patient characteristics in patients who were admitted for colonoscopy 2 age September 2016 - December 2018
Other Patient characteristics in patients who were admitted for colonoscopy 3 male/female September 2016 - December 2018 0
Other symptom characteristics in patients who were admitted for colonoscopy 1 proportion of patients with loose stools September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 2 proportion of patients with constipation September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 3 proportion of patients with altered bowel function specified September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 4 proportion of patients with abnormal radiology September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 5 proportion of patients with abnormal rectal examination September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 6 proportion of patients with rectal bleeding without obvious source September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 7 proportion of patients with rectal bleeding despite adequate treatment September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 8 proportion of high-risk patients with rectal bleeding September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 9 proportion of patients with anemia of unknown cause September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 10 proportion of patients with positive fecal occult blood test September 2016 - December 2018
Other symptom characteristics in patients who were admitted for colonoscopy 11 proportion of patients with increased fecal calprotectin September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 1 Proportion of patients with polyps high-grade/low grade dysplasia September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 2 Proportion of patients with diverticulosis September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 3 Proportion of patients with inflammation unspecified September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 4 Proportion of patients with IBD September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 5 Proportion of patients with infectious colitis September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 6 Proportion of patients with microscopic colitis September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 7 Proportion of patients with diverticulitis September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 8 Proportion of patients with hemorrhoids September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 9 Proportion of patients with angiodysplasia September 2016 - December 2018
Other Endoscopic finding in patients who were admitted for colonoscopy 10 Proportion of patients with no findings. September 2016 - December 2018
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 1 proportion of patients with weight loss >10% Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 2 proportion of patients with loss of appetite Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 3 proportion of patients with dysphagia Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 4 proportion of patients with vomiting Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 5 proportion of patients with jaundice Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 6 proportion of patients with GERD/oesofagitis Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 7 proportion of patients with gastritis Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 8 proportion of patients with peptic ulcer disease Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 9 proportion of patients with dysplasia/cancer Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 10 proportion of patients with IBD Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 11 proportion of patients with celiac disease Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 12 proportion of patients who meet Rome IV criteria for functional dyspepsia. Jan 2019-April 2020
Other Symptom characteristics in patients < 50 years who were admitted for a gastroscopy 13 proportion of patients with other unspecified pathology Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 1 male/female Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 2 proportion of patients who smoke Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 3 proportion of patients with age 18-29, age 30-39, age 40-49. Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 4 proportion of patients using NSAIDs/ASA Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 5 proportion of patients who had done a h. pylori test Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 6 proportion of patients with a positive h. pylori test Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 7 proportion of patients who were eradicated after a positive h. pylori test Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 8 ethnicity of patients (proportion caucasian origin, African origin, arabic origin, asian origin) Jan 2019-April 2020
Other Patients characteristics in patients < 50 years who were admitted for a gastroscopy 9 days between referral and gastroscopy Jan 2019-April 2020
Primary All confirmed colorectal cancer cases that were diagnosed via colonoscopy. The proportion of patients that was admitted to the department of surgery with confirmed colorectal cancer, diagnosed according to the standardized course of care for colorectal cancer. between September 2016 and December 2018
Primary Proportion of patients that was diagnosed with colorectal cancer. with colorectal cancer All patients that were admitted to the endoscopy unit according to the standardized course of care for colorectal cancer. between September 2016 and December 2018
Primary Presence of upper GI pathology The proportion of upper GI pathology in all patients <50 years who were admitted for a gastroscopy between Jan 2019-April 2020
Secondary route of colorectal cancer diagnosis 1 The proportion of patients with confirmed colorectal cancer that was diagnosed with colonoscopy according to the standardized chain of care for colorectal cancer. January 2016 and December 2018
Secondary route of colorectal cancer diagnosis 2 The proportion of patients with confirmed colorectal cancer that was diagnosed with routine colonoscopy. January 2016 and December 2018
Secondary Localization of colorectal cancer The site of the tumor in confirmed colorectal cancer January 2016 and December 2018
Secondary tumor characteristics of colorectal cancer 1 The stage of the tumor in confirmed colorectal cancer January 2016 and December 2018
Secondary tumor characteristics of colorectal cancer 2 The histology of the tumor in confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 1 proportion of patients with changes in bowel habits >4 weeks in patients with confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 2 proportion of patients with radiology in patients with confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 3 proportion of patients with abnormal rectal finding via palpation or rectoscopy in patients with confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 4 proportion of patients with rectal bleeding without obvious source in patients with confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 5 proportion of patients with rectal bleeding despite adequate treatment of bleeding source in patients with confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 6 proportion of patients with rectal bleeding in high-risk patients with confirmed colorectal cancer January 2016 and December 2018
Secondary symptom characteristics of colorectal cancer 7 proportion of patients with bleeding anemia of unknown source in patients with confirmed colorectal cancer January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 1 male/female January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 2 age January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 3 hemoglobine value January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 4 calprotectin value January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 5 Days between referral and colonoscopy January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 6 referral from primary health care yes/no January 2016 and December 2018
Secondary patient characteristics of colorectal cancer 7 referral year: 2017/2017/2018 January 2016 - December 2018
See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1